| Status | Awaiting development |
| Technology type | Medicine |
| Decision | None selected |
| Process | TA |
| ID number | 4052 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 November 2023 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early July 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid- September 2024. |
| 30 March 2023 | Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer have been revised. It is anticipated that the appraisal will begin in early-March 2024 when we will write to you about how you can get involved. |
| 19 December 2022 | As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in mid-April 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late June 2024. |
For further information on our processes and methods, please see our CHTE processes and methods manual